Endocrine Abstracts

Adjuvant treatment for post-menopausal women with early breast cancer (BC) includes aromatase inhibitors (AI), known to decrease bone mineral density (BMD). In this study, we investigate whether denosumab is a valid second option for patients unable to receive standard adjuvant i.v. zoledronic acid (ZA). In total, 212 patients have been evaluated after they did not receive ZA. Of those 194 were included. After evaluation by an endocrinologist, all patients were offered ZA as t...

Bone loss in chronic autoimmune inflammatory diseases is a major clinical problem. Inflammation-mediated osteoposis (IMO) is the first animal model of generalized osteoporosis resulting from inflammation. The P2×7 receptor, an ATP-gated ion-channel, is primarily expressed on immune and bone cells. ATP is now seen as a novel inflammatory mediator, with P2×7 as main target of the pro-inflammatory activity. The P2×7-receptor has a regulatory role in bone formation ...

The calcium receptor (CASR) serves as one of the main regulators of the calcium homeostasis. CASR is expressed in among other tissues parathyroid chief cells and kidney tubule cells. It has been hypothesized that CASR gene variations are responsible for low circulating calcium levels together with hypercalciuria and thereby increased risk of kidney stones. The CASR gene polymorphism A986S has been shown associated to elevated serum calcium levels in vivo<...

Objective: Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer. Weight gain is one of the observed side effects of both chemotherapy and other cancer treatments, however, the mechanism is not well-described. In this study, we aimed to assess thyroid function before- and after the course of chemotherapy for early breast cancer.Methods: This study is a 5-year prospective cohort study of patients diagnosed with early brea...

Introduction: Aromatase inhibitors, such as Letrozole or Exemestane, are often used as adjuvant treatment for post-menopausal breast cancer. However, they are known to reduce bone mineral density (BMD). Furthermore, breast cancer patients often undergo chemotherapy with drugs associated to BMD loss by themselves. Therefore, patients treated for breast cancer are subject to a considerable risk of BMD loss, and to alleviate this the treatments are normally combined with an anti-...

Background: Breast cancer survivors are a growing population due to improved treatment. It is known that postmenopausal women treated for breast cancer may experience weight gain and increased insulin resistance, but detailed knowledge on how chemotherapy impact metabolic and endocrine mechanisms remain unknown. Objective: We performed a thorough, preliminary study to elucidate the differing mechanisms of post-prandial absorption and metabolism in postme...

Background: Observational studies indicate that breast cancer survivors more often are diagnosed with type 2 diabetes mellitus (T2DM) up to several years after treatment completion. As the population of breast cancer survivors increase due to improved diagnostic and treatment methods the importance of understanding possible long-term side effects of the treatment such as T2DM becomes more central. It is reported that women receiving adjuvant chemotherapy experience weight gain...

Background: Through the decades, aromatase inhibitor maintenance therapy for patients with postmenopausal non-metastatic estrogen receptor-positive breast cancer has improved significantly. This study focuses on the patient’s further breast cancer course and clarifies the extensive symptom burden that the endocrinologist should be aware of.Aim: The study aims to gain insight into a potential gap between the endocrine symptoms outlined in guidelines ...

Aim: Aim of the study was to assess the effectiveness of the structured lifestyle intervention in diabetes type 2 high risk people.Methods: The De-Plan Project participants were selected based on FINDRISK over 14. Exclusion criteria were known or OGTT diabetes. Intervention completed by 175 participants consisted of 10 group sessions on lifestyle changes, diet and physical activity education, and 6 telephone motivation sessions and voluntary physical act...

Background: Patients with hypoparathyroidism experience significant physical and cognitive symptoms and reduced health-related quality of life (HRQoL). Conventional therapy for hypoparathyroidism does not fully alleviate diminished HRQoL. The Hypoparathyroidism Patient Experience Scales (HPES) were developed to assess disease-specific physical and cognitive symptoms as well as the impact of hypoparathyroidsm on HRQol. TransCon PTH, an investigational long-acting prodrug of par...